Generic Name and Formulations:
Epinephrine 0.1mg, 0.15mg, 0.3mg; pre-filled auto-injector (includes audible and visible cues for use).
Indications for AUVI-Q:
Emergency treatment of allergic reactions (Type 1) including anaphylaxis.
Adults and Children:
<7.5kg: not established. Inject IM or SQ only into the anterolateral aspect of the thigh. 7.5–15kg: 0.1mg. 15–30kg: 0.15mg. ≥30kg: 0.3mg. May repeat another dose if needed.
The presence of sulfite in this product should not deter use. Cardiovascular disease. Hypertension. Hyperthyroidism. Diabetes. Parkinson's disease. Injection-related complications: do not inject intravenously or into buttock (risk of Clostridial infections), digits, hands, or feet; hold leg firmly and limit movement in children prior to and during injection. Advise patient to seek medical help immediately. Train patient in use of device. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by MAOIs, tricyclic antidepressants, levothyroxine, antihistamines (eg, chlorpheniramine, tripelennamine, diphenhydramine). May be antagonized by β-blockers (eg, propranolol), α-blockers (eg, phentolamine), ergot alkaloids. Arrhythmias possible with cardiac glycosides, diuretics, or anti-arrhythmics.
Anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea, vomiting, headache, respiratory difficulties; arrhythmias; rare: serious infections (skin and soft tissue) at injection site.
Cartons—2 (w. one Auvi-Q Trainer)
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)